Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is
not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing
side effects caused by trastuzumab.
PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how well they work
compared with a placebo in reducing side effects in patients with HER2-positive breast cancer
receiving trastuzumab.